Following strengthening rumors in recent weeks, Takeda Pharmaceutical Co. Ltd. has confirmed it has finalized an agreement to shed a selected portfolio of over-the-counter (OTC) and prescription pharmaceuticals in multiple markets in the Near/Middle East and Africa to Swiss firm Acino Holding AG, for a total value of around $200m.
Takeda Sheds Select Product Assets In Mid-East, Emerging Markets To Acino
In a continued effort to pay down its debt pile from the acquisition of Shire, Takeda is to offload around 30 selected OTC and Rx products in certain Middle East and other emerging markets to private Swiss group Acino.
More from Strategy
More from Business
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.